Sorrento Therapeutics Inc (NASDAQ:SRNE) announced in a press release that the National Institutes of Health (NIH) has provided funding for the development of bispecific antibodies. Two small business grants from the NIH will allow Sorrento to use its antibody conjugation technology platform to develop antibodies for two of the NIH’s anti-bacterial immunotherapies. Sorrento’s pipeline also shows promise in anti-infectives and auto-immune diseases. Sorrento Therapeutics Inc … Continue reading Healthcare Decliners: Sorrento Therapeutics (NASDAQ:SRNE), Fibrocell Science (NYSEMKT:FCSC), TG Therapeutics (NASDAQ:TGTX), CombiMatrix (NASDAQ:CBMX)